Annual report
4528.TEDINET S100YA20
Period2025-04-01 → 2026-03-31
Filed2026-06-15
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Amended by S100YOIE (2026-07-08).
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥515.8bn | 2025-04-01 → 2026-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥486.9bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥502.7bn | 2023-04-01 → 2024-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥447.2bn | 2022-04-01 → 2023-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥361.4bn | 2021-04-01 → 2022-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥92.2bn | 2025-04-01 → 2026-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥59.7bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥92.7bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥59.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥163.7bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥143.5bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥105.0bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥69.8bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥50.0bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥128.0bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥112.7bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥80.5bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥69.9bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥50.2bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥1.11T | at 2026-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.06T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥913.7bn | at 2024-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥882.4bn | at 2023-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥739.2bn | at 2022-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥249.9bn | at 2026-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥275.8bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥856.6bn | at 2026-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥788.2bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥798.6bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥850.7bn | at 2026-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥782.5bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥793.0bn | at 2024-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥741.9bn | at 2023-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥655.9bn | at 2022-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥237.0bn | at 2026-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥204.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥166.1bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥96.1bn | at 2023-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥69.1bn | at 2022-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥136.8bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥82.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥110.7bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥159.6bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥61.8bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥39.9bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥136.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥48.1bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥100.3bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥6.0bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥65.5bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥94.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥89.8bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥32.5bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥60.2bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥148.49 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥106.55 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥266.61 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥230.85 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥162.19 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥148.41 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥106.41 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥266.57 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥230.79 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥162.16 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,810.44 | at 2026-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,665.61 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,688.43 | at 2024-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,519.19 | at 2023-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,343.4 | at 2022-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 76.9% | at 2026-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 73.5% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 86.8% | at 2024-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 84.1% | at 2023-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 88.7% | at 2022-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 8.5% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.4% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 16.7% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 16.1% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.5% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 4,206 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 4,287 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 3,853 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 3,761 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 3,687 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥458.9bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥451.8bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥498.8bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥441.2bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥357.0bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥103.7bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥114.7bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥101.4bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥112.3bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥188.0bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥150.8bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥121.1bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥106.0bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥127.5bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥79.7bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥102.4bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥152.9bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥117.2bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥94.6bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.05T | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥1.03T | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥847.3bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥804.6bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥661.9bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥209.1bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥229.0bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥844.8bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥797.6bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥750.2bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥685.6bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥599.2bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥199.8bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥172.0bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥169.72 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥218.02 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥318.51 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥239.96 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥190.51 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥169.67 | 2025-04-01 → 2026-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥217.98 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥318.49 | 2023-04-01 → 2024-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥239.94 | 2022-04-01 → 2023-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥190.49 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥80 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥80 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥80 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥56 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,797.89 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,697.77 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,597.16 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,403.84 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,226.79 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 80.2% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.7% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.5% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.2% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.5% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 9.7% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.2% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 21.3% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 18.2% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.1% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 498,692,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 498,692,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 498,692,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 517,425,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 528,341,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 3,396 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 3,464 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 3,437 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 3,381 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 3,354 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 2
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceutical Productsreportable segment | employees | at 2026-03-31 | 4206 pure |
| Pharmaceutical Productsreportable segment | employees | at 2026-03-31 | 3396 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,929
| Item | Context | Value | Unit |
|---|---|---|---|
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row32Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row32Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row33Member | Original text (Japanese)（株）ほくやく・竹山ホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row33Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row33Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row34Member | Original text (Japanese)（株）バイタルケーエスケー・ＨＤ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row34Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row34Member | Original text (Japanese)有（注12） | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row35Member | Original text (Japanese)塩野義製薬（株） | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row35Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row35Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row36Member | Original text (Japanese)(株)meito（注13） | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row36Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row36Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row37Member | Original text (Japanese)（株）ヤクルト本社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row37Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row37Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row38Member | Original text (Japanese)久光製薬（株） | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row38Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row38Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row39Member | Original text (Japanese)（株）日立製作所 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row39Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row39Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row40Member | Original text (Japanese)（株）大和証券グループ本社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row40Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row40Member | Original text (Japanese)有 | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row2Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row3Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row4Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row5Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row6Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row7Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row8Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row9Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row10Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row11Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row12Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row13Member | Text · Plus | |
| Name of securities investment equity securities reclassified from held for purposes other than pure investment to held for pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)キッセイ薬品工業（株） | |
| Fiscal year of change in purpose of shareholding investment shares reclassified from held for purposes other than pure investment to held for pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)2023年3月期 | |
| Reason for change in purpose of shareholding and policy on holding or sale of shares after change investment shares reclassified from held for purposes other than pure investment to held for pure investment reporting company | CurrentYearInstant_Row1Member | Text · Plus | |
| Name of securities investment equity securities reclassified from held for purposes other than pure investment to held for pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)カルナバイオサイエンス（株） | |
| Fiscal year of change in purpose of shareholding investment shares reclassified from held for purposes other than pure investment to held for pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)2022年3月期 | |
| Reason for change in purpose of shareholding and policy on holding or sale of shares after change investment shares reclassified from held for purposes other than pure investment to held for pure investment reporting company | CurrentYearInstant_Row2Member | Text · Plus | |
| Basic policy on human resources strategy employees etc (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | Original text (Japanese)東洋製薬化成株式会社 | |
| Description of fact that consolidated financial statements have been prepared in accordance with IFRS financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |